Alcon showcases new phakic lens

Article

Following CE mark approval last month, Alcon proudly showcased the latest offering to its lens family; the AcrySof phakic lens.

Following CE mark approval last month, Alcon proudly showcased the latest offering to its lens family; the AcrySof phakic lens.

Indicated for the treatment of moderate to high levels of myopia, this angle-supported phakic lens induced a gain of one or more lines of best corrected spectacle visual acuity (BSCVA) in over 50% of the 360 patients involved in a recent clinical trial. It also delivered significant improvements in uncorrected visual acuity (UCVA) that was on average better than 20/25. Furthermore, an impressive 95% of patients in the trial agreed that they would have the lens implanted again, given the choice.

Some patients were followed for up to three years and, during this time, only minimal central and peripheral endothelial cell loss was reported.

The AcrySof phakic lens is foldable, it is available in four lengths and in refractive power ranges from -6.0 to -16.5 D. The lens is not yet available in the US.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Thomas Bosshard stands at the Oertli Instruments booth at the ESCRS meeting
Eva Kim, MD, speaks about her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.
© 2024 MJH Life Sciences

All rights reserved.